An Enterococcal Phage-derived Enzyme Suppresses Graft-versus-host Disease
Authors
Affiliations
Changes in the gut microbiome have pivotal roles in the pathogenesis of acute graft-versus-host disease (aGVHD) after allogenic haematopoietic cell transplantation (allo-HCT). However, effective methods for safely resolving gut dysbiosis have not yet been established. An expansion of the pathogen Enterococcus faecalis in the intestine, associated with dysbiosis, has been shown to be a risk factor for aGVHD. Here we analyse the intestinal microbiome of patients with allo-HCT, and find that E. faecalis escapes elimination and proliferates in the intestine by forming biofilms, rather than by acquiring drug-resistance genes. We isolated cytolysin-positive highly pathogenic E. faecalis from faecal samples and identified an anti-E. faecalis enzyme derived from E. faecalis-specific bacteriophages by analysing bacterial whole-genome sequencing data. The antibacterial enzyme had lytic activity against the biofilm of E. faecalis in vitro and in vivo. Furthermore, in aGVHD-induced gnotobiotic mice that were colonized with E. faecalis or with patient faecal samples characterized by the domination of Enterococcus, levels of intestinal cytolysin-positive E. faecalis were decreased and survival was significantly increased in the group that was treated with the E. faecalis-specific enzyme, compared with controls. Thus, administration of a phage-derived antibacterial enzyme that is specific to biofilm-forming pathogenic E. faecalis-which is difficult to eliminate with existing antibiotics-might provide an approach to protect against aGVHD.
Shi Y, Chen Z, Fang T, Chen X, Deng Y, Qin H Imeta. 2025; 4(1):e265.
PMID: 40027479 PMC: 11865350. DOI: 10.1002/imt2.265.
Oral inflammation and microbiome dysbiosis exacerbate chronic graft-versus-host disease.
Kambara Y, Fujiwara H, Yamamoto A, Gotoh K, Tsuji S, Kunihiro M Blood. 2024; 145(8):881-896.
PMID: 39693612 PMC: 11867138. DOI: 10.1182/blood.2024024540.
Bacteriophages and their potential for treatment of metabolic diseases.
Deng Y, Jiang S, Duan H, Shao H, Duan Y J Diabetes. 2024; 16(11):e70024.
PMID: 39582431 PMC: 11586638. DOI: 10.1111/1753-0407.70024.
A Comprehensive Review on Phage Therapy and Phage-Based Drug Development.
Cui L, Watanabe S, Miyanaga K, Kiga K, Sasahara T, Aiba Y Antibiotics (Basel). 2024; 13(9).
PMID: 39335043 PMC: 11428490. DOI: 10.3390/antibiotics13090870.